The Study Of Increased Incidence Of Thrombosis In Cancer-related Anemia Mice Treated With Erythropoietin

Objective: To investingate the possibility of increased incidence of thrombosis in cancer-related anemia mice treated with erythropoietin, and to provide experimental evidence for clinical safe usage.Methods: 105 male mice , about 20±2g, were distributed in 7 groups randomly. On the first day, anemia in Group B, D, E, F and G was induced by a single dose of carboplatin (70mg/kg). Three days later, about 2.5 ×10~6 cancer cells were implanted s.c. in the right hind groin of mices in Group C, D, E, F and G Simultaneously, in Group B and E, r-HuEPO 1000U/Kg, 1500U/Kg in Group F, and 2000U/Kg in Group G was injected s.c. 3 times per week, eight times in total. Monitor the level of hemoglobin and the behavior, disp of mice kineticly. One month later, get blood from the eyes of the mice and detect the level of hematocrit, fibrinogen, plasma prothrombin time, and activated partial thromboplastin time. Carry out pathological section by routine.Results: 1. r-HuEPO exactly relieved carboplatin-induced anemia. Before injecting carboplatin, the levels of Hb among groups were equal roughly. 10 days after carboplatin injection, Hb in groups treated with r-HuEPO were higher than those without r-HuEPO (P<0.05). 2.The level of Hct improved with the improving of the dose of r-HuEPO. FIB was significantly high in Group C, E, G, so as PT. APTT in each group didn't have significant difference. 3.There were 3 mices in Group C, 5 in Group E, 4 in Group F, 6 in Group G have haemostasis in liver and/or lung by detection the pathological section. Conclusions: Erythropoietin was not found having the evidence of increasing incidence of thrombosis in cancer-related anemia mice with the dosage of 1000U/Kg and 1500U/Kg, but with the dosage of 2000U/Kg, the conclusion is on the contrary.